OxygenCeuticals is a post-procedure care specialist company that researches, develops, and manufactures cosmeceutical products under the OxygenCeuticals brand—integrating the biochemical functions of pure oxygen into skincare—along with aesthetic devices and aesthetic software. Focusing on recovery and management after aesthetic procedures, the company develops and manufactures in-house solutions that cover both pre- and post-procedure care.
OxygenCeuticals supplies its products and solutions primarily to professional clinics such as dermatology clinics, plastic surgery clinics, and medical spas both domestically and overseas. The company has developed pure oxygen-based skincare products and post-care-dedicated oxygen aesthetic devices for on-site application, concentrating on providing practical post-care solutions suitable for medical and aesthetic settings through treatment processes designed for skin that becomes sensitive immediately after procedures.
At this exhibition, OxygenCeuticals presents its skincare brand that applies the biochemical functions of pure oxygen, negative ions, and ozone, along with devices dedicated to post-procedure care. Centered on devices applicable before and after aesthetic procedures, the company plans to propose solutions that enable more systematic management of skin condition during the post-treatment recovery process.
The key exhibit, the “Astrodome Facial O2 PLUS,” is a skin aesthetic device that applies an oxygen generator utilizing a zeolite molecular sieve and is based on a therapy method that sprays high-concentration oxygen mist of over 50% onto the skin. Designed in consideration of skin sensitivity immediately after aesthetic procedures, it is a post-procedure care device intended for use in skin condition management and recovery processes.
In addition, total care solutions covering both facial and body treatments—such as the “Astrodome Facial” and “Hifuldm Facial”—are also on display. These devices are designed to reflect real-world usage environments in dermatology clinics, plastic surgery clinics, and medical aesthetic facilities, supporting more stable operation of post-procedure care processes.
OxygenCeuticals is operated as a post-procedure care program mainly in dermatology and skin aesthetic institutions and is currently used in more than 800 dermatology clinics and skin aesthetic hospitals and clinics in Korea. Applied as a post-procedure skin management program in medical settings, the solutions help medical professionals manage patients’ skin conditions more systematically after procedures.
In overseas markets, OxygenCeuticals holds skincare products registered with major regulatory authorities such as MoCRA, CPNP, and UK SCPN, and exports both devices and skincare products to more than 40 countries, including the United States, Europe, Japan, and Hong Kong. Through these activities, the company is gradually expanding its presence as a specialized post-procedure care solution provider in the global market.
Looking ahead, OxygenCeuticals plans to continue expanding its overseas business with the Middle East as a key target market. Regions such as the United Arab Emirates (UAE), Saudi Arabia, and Qatar are experiencing steady growth in demand for post-procedure care and high-functionality skincare, particularly within dermatology clinics, plastic surgery clinics, and medical spas. Leveraging this exhibition, the company is actively exploring collaboration opportunities with dermatology and plastic surgery buyers, medical spa operators, and medical and aesthetic product distribution partners in these regions.
In addition, OxygenCeuticals plans to participate in more than 18 major overseas exhibitions in 2026, including events in New York, Guangzhou, Shanghai, and Bologna. Through these activities, the company aims to actively pursue buyer development and partnership expansion in global markets, continuing its growth in the global medical aesthetic sector based on its specialized post-procedure care technologies and competitive product offerings.